Given that 50% of care is covered by Medicaid and 49% by private payors, the costs for this drug are invisible to the individual. It is administered in clinic or by home health nurses and does not typically have a co-pay structure although patients will sometimes tell providers they can’t afford it.
News of new drug approvals can be washed over with giddy hype. But not in this story, which offered perspective, context and restraint.
No discussion of costs, something we always look for and wish would be provided.
As already noted, the story explained that the drug “isn’t a magic bullet. The study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.”
Good discussion of concerns and ongoing monitoring of the drug’s safety.
The story explains the drug “isn’t a magic bullet. The study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.”
No disease-mongering of prematurity or its consequences.
The medical director of The March of Dimes was quoted throughout. (Although they are seen as having a very pro-progesterone slant that is not held by consumer/advocacy/health policy/maternity care groups in UK, Australia, and Canada. in those countries surveys of providers uniformly get low utilization responses with the reason stated being need for more data. Similar surveys of US providers (specialty and generalists) show the vast majority use >70% (as opposed to low double digits in more evidence-driven countries) and that mission creep has started. Indications for which it is not tested see regular use in the US.)
There was at least the historical perspective on “the last drug thought to prevent premature birth – a synthetic estrogen called diethylstilbesterol, or DES.”
The focus of the story is FDA approval of the drug.
Good historical context, explaining that “Interestingly, the drug is not new — it’s just taken a long and circuitous route to approval.”
It’s clear the story didn’t rely solely on a news release.
Systematic, Criteria-Driven
A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like